LP
ACOR

LMR Partners’s Acorda Therapeutics ACOR Stock Holding History

LMR Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-139
Closed -$9K – 665
2020
Q3 		$9K Sell
139
-24
-15% -$1.81K ﹤0.01% 430
2020
Q2 		$14K Buy
+163
New +$17.2K ﹤0.01% 577

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

LMR Partners's ACOR Position: Q4 2020 in Review

LMR Partners sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 139 shares — an estimated $9K sold.

LMR Partners first reported a position in ACOR in Q2 2020 and held it in 2 quarters. The position peaked at $14K in Q2 2020. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

  • LMR Partners reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
  • LMR Partners sold 139 Acorda Therapeutics shares in Q4 2020, an estimated $9K.
  • LMR Partners first reported a position in Acorda Therapeutics in Q2 2020 and held it in 2 quarters.
  • LMR Partners's Acorda Therapeutics position peaked at $14K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on LMR Partners's 13F filing for Q4 2020, filed 16 Feb 2021.